Showing results (221-230 of 1,189) with videos related to

Sort By:
Pageof 119
BMC Pharmacology & Toxicology|January 30, 2025
Systematic review and meta-analysis on the carbapenem-resistant hypervirulent Klebsiella pneumoniae isolatesMotahareh Sabaghi Qala Nou, Zahra Amirian, Fatemeh Dehghani, et al.
BMC Pharmacology & Toxicology|November 16, 2024
An in vivo and in silico probing of the protective potential of betaine against sodium fluoride-induced neurotoxicitySolomon E Owumi, Bayode J Oluwawibe, Joseph Chimezie, et al.
BMC Pharmacology & Toxicology|November 26, 2024
Effects of melatonin on the prevention of delirium in hospitalized older patients: systematic review and meta-analysisLe Liu, Xin Ma, Zejun Song, et al.
BMC Pharmacology & Toxicology|November 20, 2024
Pulrodemstat, a selective inhibitor of KDM1A, suppresses head and neck squamous cell carcinoma growth by triggering apoptosisCheng Jiang, Xiaofeng Weng, Yuqing Chen, et al.
BMC Pharmacology & Toxicology|March 20, 2025
Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) databasePuen Jiang, Kezhen Zong, Dadi Peng, et al.
BMC Pharmacology & Toxicology|March 12, 2025
Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting systemZiyi Fan, Yanan Xu, Shuding Guo, et al.
BMC Pharmacology & Toxicology|October 24, 2024
Bioequivalence study of eltrombopag 75 mg film-coated tablets under fasting conditions during the Covid-19 pandemic in healthy Caucasian male subjectsAhmet Inal, Zafer Sezer, Onur Pinarbasli, et al.
BMC Pharmacology & Toxicology|October 11, 2024
GR113808, a serotonin receptor 4 antagonist, prevents high-fat-diet-induced obesity, fatty liver formation, and insulin resistance in C57BL/6J miceMin Hee Kim, Su-Jeong Kim, Woo-Jae Park, et al.
BMC Pharmacology & Toxicology|September 12, 2024
Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system databaseQing Yang, Junyan Wang, Menghuan Wang, et al.
BMC Pharmacology & Toxicology|August 9, 2024
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance studyWanlong Lin, Yanbin Zeng, Lizhu Weng, et al.
Pageof 119